Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...

Full description

Saved in:
Bibliographic Details
Main Authors: Junjie GU, Fan BAI, Lan SONG, Yingyi WANG
Format: article
Language:ZH
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Subjects:
epidermal growth factor receptor
interstitial lung disease
lung neoplasms
osimertinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745

Similar Items